Interaction of vitamin D, homocystein and dental diseases

Interaction of vitamin D, homocystein and dental diseases

The aim of the study was to estimate the effect of ursodeoxycholic acid (UDCA) on the lipid profile, endothelial dysfunction and insulin resistance in patients with coronary heart disease (CHD) in combination with non-alcoholic steatosis. Materials and methods. The group 1 consisted of 24 patie...

Full description

Bibliographic Details
Main Authors:	O. V. Kuriata, M. M. Hrechanyk
Format:	Article
Language:	English
Published:	Zaporozhye State Medical University 2019-06-01
Series:	Zaporožskij Medicinskij Žurnal
Subjects:	coronary heart disease non-alcoholic fatty liver insulin resistance lipids vascular endothelium ursodeoxycholic acid
Online Access:	http://zmj.zsmu.edu.ua/article/view/169011/169285

Similar Items

Non-alcoholic fatty liver disease as a cause and consequence of cardio-metabolic complications. Role of the ursodeoxicholic acid in the pharmacotherapy
by: M V Maevskaya, et al.
Published: (2019-02-01)

Efficacy of ursodezoxycolic acid in the treatment of non-alcoholic fatty liver disease
by: D. T. Dicheva, et al.
Published: (2018-04-01)

The feasibility of using ursodeoxycholic acid in the treatment of patients with non-alcoholic fatty liver disease: a clinical case
by: Ye.S. Sirchak
Published: (2018-09-01)

An Effect of Ursodeoxycholic Acid on Inflammation, Steatosis and Liver Fibrosis and Atherogenesis Factors in Patients with Non-Alcoholic Fatty Liver Disease: Results of the USPEH Study
by: M. V. Mayevskaya, et al.
Published: (2020-01-01)

Dynamics of changes in lipid peroxidation and antioxidant protection under the influence of complex treatment in patients with comorbid course of non-alcoholic steatohepatitis
by: O. Yu. Filippova
Published: (2019-06-01)

Effect of Combination Therapy with Atorvastatin and Ursodeoxycholic Acid on the Course of Ischemic Heart Disease with Co-Existent Non-Alcoholic Fatty Liver Disease and Obesity
by: Nataliya Karpyshyn
Published: (2016-12-01)

Functional condition of vascular endothelium in patients with coronary heart disease in combination with non-alcoholic fatty liver disease, depending on weight and influence of statin therapy
by: O. V. Kuryata, et al.
Published: (2015-02-01)

STATINS AND URSODEOXYCHOLIC ACID: COOPERATION OR NEUTRALITY?
by: I. N. Grigorieva, et al.
Published: (2016-01-01)

An open-label randomized control study to compare the efficacy of vitamin e versus ursodeoxycholic acid in nondiabetic and noncirrhotic Indian NAFLD patients
by: Pathik Parikh, et al.
Published: (2016-01-01)

TyG index is positively associated with risk of CHD and coronary atherosclerosis severity among NAFLD patients
by: Fan, H., et al.
Published: (2022)

How to avoid statin hepatotoxicity in patients with obesity and liver disease? Focus on the combination of ursodeoxycholic acid and atorvastatin
by: O. N. Korneeva, et al.
Published: (2012-12-01)

Effect of Ginger Powder Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial
by: Rafie R, et al.
Published: (2020-01-01)

Influence of ursodeoxycholic acid on insulin resistance in patients with metabolic syndrome
by: V.I. Pankiv
Published: (2018-04-01)

Non-alcoholic fatty liver disease associated with obesity: features ursodeoxycholic acid
by: D. I. Trukhan, et al.
Published: (2019-04-01)

Optimization of therapy for hepatobiliary disorders in psoriatic patients
by: I V Kozlova, et al.
Published: (2017-12-01)

A randomized double-blind study of the short-time treatment of obese patients with nonalcoholic fatty liver disease with ursodeoxycholic acid
by: V.N. Santos, et al.
Published: (2003-06-01)

Algunas variables bioquímicas en adolescentes obesos con antecedente de bajo peso al nacer
by: María del Carmen Valdés Alonso, et al.

Therapeutic correction of liver and biliary tract pathology among adolescents with obesity
by: L.K. Parkhomenko, et al.
Published: (2017-04-01)

Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview
by: Asad Dajani, et al.
Published: (2016-01-01)

The effect of vitamin D supplementation on blood sugar and different indices of insulin resistance in patients with non-alcoholic fatty liver disease (NAFLD)
by: Mehdi Foroughi, et al.
Published: (2016-01-01)

Functional gall-bladder disorders and non-alcoholic fatty liver disease: clinical features and new approaches to therapy
by: S. N. Mekhtiev, et al.
Published: (2020-10-01)

Low vitamin D level was associated with metabolic syndrome and high leptin level in subjects with nonalcoholic fatty liver disease: a community-based study
by: Li-Wei Chen, et al.
Published: (2019-07-01)

TRIB1 rs17321515 gene polymorphism increases the risk of coronary heart disease in general population and non-alcoholic fatty liver disease patients in Chinese Han population
by: Qun Liu, et al.
Published: (2019-08-01)

Lessons from Mouse Models of High-Fat Diet-Induced NAFLD
by: Yasuo Terauchi, et al.
Published: (2013-10-01)

Are patients with alcohol-related fatty liver at increased risk of coronary heart disease?
by: Dong Hyun Sinn, et al.
Published: (2014-06-01)

Insulin Resistance and NAFLD: A Dangerous Liaison beyond the Genetics
by: Melania Manco
Published: (2017-08-01)

The Role of Fatty Acids in Non-Alcoholic Fatty Liver Disease Progression: An Update
by: Aleksandra Hliwa, et al.
Published: (2021-06-01)

Non-alcoholic fatty liver disease: features of metabolic changes at different stages of the disease
by: Yu.M. Stepanov, et al.
Published: (2018-02-01)

Glutamate–Serine–Glycine Index: A Novel Potential Biomarker in Pediatric Non-Alcoholic Fatty Liver Disease
by: Simone Leonetti, et al.
Published: (2020-12-01)

Non-Alcoholic Fatty Liver Disease (NAFLD) - Is it an Emerging Risk Factor for Coronary Artery Disease? : Preliminary study in a local Indian population
by: Manopriya Thiruvagounder, et al.
Published: (2010-08-01)

The role of acylated ghrelin and unacylated ghrelin in the blood and hypothalamus and their interaction with nonalcoholic fatty liver disease
by: Xia Liu, et al.
Published: (2020-09-01)

SCHEME FOR COMBINED USE OF STATINS AND URSODEOXYCHOLIC ACID IN PATIENTS WITH A HIGH RISK OF CARDIOVASCULAR EVENTS AND CONCOMITANT NON-ALCOHOLIC FATTY LIVER DISEASE: PROBLEMS OF PRACTICAL APPLICATION
by: S. N. Bel'diev
Published: (2017-03-01)

Non-alcoholic fatty liver disease: From insulin resistance to mitochondrial dysfunction Enfermedad grasa del hígado no alcohólica: Desde la resistencia a la insulina a la disfunción mitocondrial
by: J. A. Solís Herruzo, et al.
Published: (2006-11-01)

Effect of silybin on high-fat-induced fatty liver in rats
by: Jiayin Yao, et al.
Published: (2011-07-01)

A New Targeted Lipidomics Approach Reveals Lipid Droplets in Liver, Muscle and Heart as a Repository for Diacylglycerol and Ceramide Species in Non-Alcoholic Fatty Liver
by: Christina Preuss, et al.
Published: (2019-03-01)

Utility of ALT Concentration in Men and Women with Nonalcoholic Fatty Liver Disease: Cohort Study
by: Ki-Chul Sung, et al.
Published: (2019-04-01)

Altered Fatty Acid Metabolism-Related Gene Expression in Liver from Morbidly Obese Women with Non-Alcoholic Fatty Liver Disease
by: Teresa Auguet, et al.
Published: (2014-12-01)

Adiponectin and parameters of glucose and lipid metabolism at different clinical and morphological stages of non-alcoholic fatty liver disease in patients with abdominal obesity
by: K A Komshilova, et al.
Published: (2014-10-01)

Diagnostic significance of the newest biomarkers of steatosis progression in patients with stable coronary heart disease, combined with nonalcoholic fatty liver disease
by: I. I. Vakalyuk, et al.
Published: (2018-03-01)

Chronic Alcohol Consumption is Inversely Associated with Insulin Resistance and Fatty Liver in Japanese Males
by: Takemi Akahane, et al.
Published: (2020-04-01)

Cannot write session to /tmp/vufind_sessions/sess_jaiki939tlmo32cca87fi0b80r